Abstract | BACKGROUND: METHODS: Data were pooled for 140 patients from three multicenter, prospective, single-arm, open-label phase II studies evaluating the efficacy and safety of olanzapine for managing nausea and vomiting induced by carboplatin-based chemotherapy. Multivariable logistic regression analyses were performed to determine the patient-related risk factors. RESULTS: Regarding the endpoints of carboplatin regimen-induced nausea and vomiting control, the complete response, complete control, and total control rates during the overall study period were 87.9, 86.4, and 72.9%, respectively. No treatment-related adverse events of grade 3 or higher were observed. The multivariable logistic regression models revealed that only younger age was significantly associated with an increased risk of non-total control. Surprisingly, there was no significant difference in CINV control between the patients treated with or without neurokinin-1 receptor antagonist. CONCLUSIONS:
|
Authors | Senri Yamamoto, Hirotoshi Iihara, Ryuji Uozumi, Hitoshi Kawazoe, Kazuki Tanaka, Yukiyoshi Fujita, Masakazu Abe, Hisao Imai, Masato Karayama, Yoh Hayasaki, Chiemi Hirose, Takafumi Suda, Kazuto Nakamura, Akio Suzuki, Yasushi Ohno, Ken-Ichirou Morishige, Naoki Inui |
Journal | BMC cancer
(BMC Cancer)
Vol. 21
Issue 1
Pg. 832
(Jul 19 2021)
ISSN: 1471-2407 [Electronic] England |
PMID | 34281514
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Copyright | © 2021. The Author(s). |
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Carboplatin
(adverse effects)
- Female
- Humans
- Male
- Middle Aged
- Nausea
(chemically induced, drug therapy)
- Olanzapine
(pharmacology, therapeutic use)
- Prospective Studies
- Vomiting
(chemically induced, drug therapy)
|